| 1013 |
Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis
|
2025-01-31 |
591 |
| 1012 |
Surgical Management of Intracerebral Hemorrhage: New Light on the Horizon?
|
2025-01-31 |
1,039 |
| 1011 |
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
|
2025-01-31 |
609 |
| 1010 |
Large-Core Ischemic Stroke Endovascular Treatment: A Science Advisory From the American Heart Association
|
2024-12-31 |
870 |
| 1009 |
Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial
|
2024-12-31 |
600 |
| 1008 |
Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage
|
2024-12-31 |
520 |
| 1007 |
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
|
2024-12-03 |
797 |
| 1006 |
Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours
|
2024-12-03 |
887 |
| 1005 |
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial
|
2024-12-03 |
845 |
| 1004 |
White Matter Hyperintensities and Cognitive Functions in People With the R544C Variant of the NOTCH3 Gene Without Stroke or Dementia
|
2024-11-01 |
974 |
| 1003 |
Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack
|
2024-11-01 |
1,362 |
| 1002 |
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
|
2024-11-01 |
694 |
| 1001 |
Asundexian versus Apixaban in Patients with Atrial Fibrillation
|
2024-09-27 |
883 |
| 1000 |
Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis The BASIS Randomized Clinical Trial
|
2024-09-27 |
673 |
| 999 |
Thrombectomy for Stroke With Large Infarct on Noncontrast CT : The TESLA Randomized Clinical Trial
|
2024-09-27 |
996 |
HOME
LOGIN
